Efficacy and Safety of Alteplase Combined with Urinarykallid for Intravenous Thrombolysis on Acute Cerebral Infarction

IF 0.5 4区医学 Q4 NEUROSCIENCES Neurochemical Journal Pub Date : 2024-05-24 DOI:10.1134/s1819712424010203

Jiahui Shao, Linyi Bao, Xinchun Jin, Haimiao Jin, Yun Chen

{"title":"Efficacy and Safety of Alteplase Combined with Urinarykallid for Intravenous Thrombolysis on Acute Cerebral Infarction","authors":"Jiahui Shao, Linyi Bao, Xinchun Jin, Haimiao Jin, Yun Chen","doi":"10.1134/s1819712424010203","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Abstract</h3>This study aimed to explore the efficacy and safety of alteplase combined with urinarykallid for the intravenous thrombolysis of patients with acute cerebral infarction. Patients (n = 125) who were admitted to our hospital were included and divided into Group A (n = 60) and Group B (n = 65). Patients in Group A were treated with alteplase for intravenous thrombolysis, based on which urinarykallid was administered to patients in Group B as a combination treatment. Compared to Group A, Group B was significantly lower in hs-CRP and TNF-α levels (p < 0.001), total incidence of adverse reactions (p < 0.05), and NIHSS score (p < 0.001) and higher in IL-10 level (p < 0.001), total effective rate (markedly effective + effective/total cases × 100%. Compared to the single administration of alteplase, the combination of alteplase and urinarykallid for the intravenous thrombolysis of patients with acute cerebral infarction can achieve better efficacy at a lower incidence of adverse reactions and play a more significant role in clinical treatment.","PeriodicalId":19119,"journal":{"name":"Neurochemical Journal","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurochemical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1134/s1819712424010203","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

This study aimed to explore the efficacy and safety of alteplase combined with urinarykallid for the intravenous thrombolysis of patients with acute cerebral infarction. Patients (n = 125) who were admitted to our hospital were included and divided into Group A (n = 60) and Group B (n = 65). Patients in Group A were treated with alteplase for intravenous thrombolysis, based on which urinarykallid was administered to patients in Group B as a combination treatment. Compared to Group A, Group B was significantly lower in hs-CRP and TNF-α levels (p < 0.001), total incidence of adverse reactions (p < 0.05), and NIHSS score (p < 0.001) and higher in IL-10 level (p < 0.001), total effective rate (markedly effective + effective/total cases × 100%. Compared to the single administration of alteplase, the combination of alteplase and urinarykallid for the intravenous thrombolysis of patients with acute cerebral infarction can achieve better efficacy at a lower incidence of adverse reactions and play a more significant role in clinical treatment.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿替普酶联合尿囊素静脉溶栓治疗急性脑梗塞的有效性和安全性

摘要本研究旨在探讨阿替普酶联合尿激酶静脉溶栓治疗急性脑梗死患者的有效性和安全性。研究纳入了本院收治的患者（n = 125），并将其分为 A 组（n = 60）和 B 组（n = 65）。A 组患者接受阿替普酶静脉溶栓治疗，B 组患者在此基础上接受尿激酶联合治疗。与A组相比，B组患者的hs-CRP和TNF-α水平（p <0.001）、不良反应总发生率（p <0.05）和NIHSS评分（p <0.001）明显降低，而IL-10水平（p <0.001）、总有效率（显效+有效/总例数×100%）则明显提高。与单一给予阿替普酶相比，阿替普酶与尿激酶联合应用于急性脑梗死患者的静脉溶栓治疗，能够以较低的不良反应发生率取得更好的疗效，在临床治疗中发挥的作用更加显著。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neurochemical Journal 医学-神经科学

自引率

20.00%

发文量

审稿时长

>12 weeks

期刊介绍： Neurochemical Journal (Neirokhimiya) provides a source for the communication of the latest findings in all areas of contemporary neurochemistry and other fields of relevance (including molecular biology, biochemistry, physiology, neuroimmunology, pharmacology) in an afford to expand our understanding of the functions of the nervous system. The journal presents papers on functional neurochemistry, nervous system receptors, neurotransmitters, myelin, chromaffin granules and other components of the nervous system, as well as neurophysiological and clinical aspects, behavioral reactions, etc. Relevant topics include structure and function of the nervous system proteins, neuropeptides, nucleic acids, nucleotides, lipids, and other biologically active components. The journal is devoted to the rapid publication of regular papers containing the results of original research, reviews highlighting major developments in neurochemistry, short communications, new experimental studies that use neurochemical methodology, descriptions of new methods of value for neurochemistry, theoretical material suggesting novel principles and approaches to neurochemical problems, presentations of new hypotheses and significant findings, discussions, chronicles of congresses, meetings, and conferences with short presentations of the most sensational and timely reports, information on the activity of the Russian and International Neurochemical Societies, as well as advertisements of reagents and equipment.